These considerations, combined with the observation that tumor vessels can develop resistance to anti-VEGF therapy 5, highlight the need to identify effective anti-angiogenesis therapies that are based on VEGF-independent targets and can be used in combination with anti-VEGF independent therapy to improve outcomes for patients. This evidence concerns the gene VEGFA and neoplasm.